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PediatricsTaliglucerase alfa is a plant cell–expressed beta-glucocerebrosidase approved in the United States, Israel,
Australia, Canada, and other countries for enzyme replacement therapy in adults with Type 1 Gaucher disease
(GD), for treatment of pediatric patients in theUnited States, Australia, and Canada, and for the hematologicman-
ifestations of Type 3 GD in pediatric patients in Canada. This multicenter, randomized, double-blind, parallel-
dose, 12-month study assessed efﬁcacy and safety of taliglucerase alfa in pediatric patients with GD. Eleven chil-
dren were randomized to taliglucerase alfa 30U/kg (n = 6) or 60U/kg (n = 5) per infusion every other week.
From baseline to month 12, the following changes were noted in the taliglucerase alfa 30-U/kg and 60-U/kg
dose groups, respectively: median hemoglobin concentrations increased by 12.2% and 14.2%; the interquartile
ranges of median percent change in hemoglobin levels from baseline were 20.6 and 10.4, respectively; mean
spleen volume decreased from 22.2 to 14.0 multiples of normal (MN) and from 29.4 to 12.9MN; mean liver vol-
ume decreased from 1.8 to 1.5 MN and from 2.2 to 1.7 MN; platelet counts increased by 30.9% and 73.7%; and
chitotriosidase activity was reduced by 58.5% and 66.1%. Nearly all adverse events were mild/moderate, unrelat-
ed to treatment, and transient. One patient presentedwith treatment-related gastroenteritis reported as a serious
adverse event due to the need for hospitalization for rehydration. No patient discontinued. These data suggest
that taliglucerase alfa has the potential to be a therapeutic treatment option for children with GD. This study
was registered at www.clinicaltrials.gov as NCT01132690.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Gaucher disease (GD) is a rare lysosomal storage disorderwith an esti-
mated prevalence of approximately 1 in 111,000 to 1 in 57,000 [1,2], with
higher prevalence noted within the Ashkenazi Jewish population of 1 in
855 [1]. This disease results from mutations in the gene for beta-
glucocerebrosidase; insufﬁcient activity of this enzyme leads to
accumulation of glucocerebroside in macrophages, which leads to multi-
organ pathology [1]. Three main types of GD are recognized, and Type 1
is themost commonwith the key clinical manifestations of splenomegaly,uestionnaire; ERT, enzyme re-
D, Gaucher disease;MN,multi-
edek Medical Center, 12 Bayit
2 6517979.
erlis@conexion.com.py
brahamov), elstein@szmc.org.il
talix.com (E. Brill-Almon),
. This is an open access article underhepatomegaly, anemia, and thrombocytopenia and a lack of primary cen-
tral nervous system involvement that is characteristic of Types 2 and 3 [1].
Gaucher disease has marked heterogeneity in age of onset, disease
manifestations, and clinical course [1,3–5]. About half of patients with
Type 1 GD are diagnosed before 20 years of age [1]. Symptomatic
patients diagnosed in childhood tend to havemore severe disease man-
ifestations [5], and are expected to experience an overall greater burden
of disease [6,7]. Enzyme replacement therapy (ERT) is recommended
for patients, including children, with GD whomanifest signs and symp-
toms [6–8]. Early intervention with ERT in symptomatic children may
prevent the development of irreversible pathology [6–8]. Treatment is
also important to improve growth and reduce the impact of the disease
on physical and psychosocial development [6–8].
Taliglucerase alfa is an ERT that is approved in the United States,
Israel, Brazil, Chile, Australia, Canada, and other countries for the treat-
ment of Type 1 GD in adults, for treatment of pediatric patients in the
United States, Australia, and Canada, and for hematologic manifesta-
tions in pediatric patients with Type 3 GD in Canada. It is the ﬁrst
approved plant cell–expressed recombinant therapeutic protein [9].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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advantages, such as the inability to be contaminated with or propa-
gate mammalian pathogens, along with a potential lower cost
[9–12]. In the taliglucerase alfa clinical development program, the
phase 1 study was conducted in 6 healthy adult volunteers [13].
Taliglucerase alfa safety and efﬁcacy were then investigated in the
phase 3, ﬁrst-time-in-GD patients, pivotal, 9-month, double-blind,
randomized, parallel-group trial in treatment-naïve adult patients
[14]. Although it was not pre-speciﬁed in the trial design, all 29
patients completing the study had Type 1 GD. Treatment with
taliglucerase alfa 30 U/kg and 60 U/kg (per infusion every other
week) was associated with signiﬁcant reductions in spleen volume,
the primary end point, from baseline to 9 months. Secondary end
points included signiﬁcant reductions in liver volume and signiﬁ-
cant increases in hemoglobin concentrations and platelet counts
from baseline to 9 months. Treatment was generally well tolerated
and all drug-related adverse events (AEs) were mild/moderate and
transient.
The objective of this study was to assess the efﬁcacy and safety of
taliglucerase alfa in pediatric patients with GD at the same doses of
30 U/kg and 60 U/kg per infusion every other week as with the pivotal
phase 3 trial in adult patients.Material and methods
Study design
This study was a phase 3B multicenter, randomized, double-blind,
2-dose trial of taliglucerase alfa (30 U/kg and 60 U/kg per infusion
every other week) in pediatric patients (aged 2 to b18 years). The trial
was conducted at 3 centers (Shaare Zedek Medical Center, Jerusalem,
Israel; Instituto Privado de Hematologia e Investigacion Clinica
[I.P.H.I.C.], Asuncion, Paraguay; and the Morningside Medi-Clinic
Johannesburg, South Africa). This trial (PB-06-005; NCT01132690) was
designed and conducted in compliance with the ethical principles
of Good Clinical Practice guidelines and all local regulations for each cen-
ter, and in accordance with the Declaration of Helsinki. Investigators ob-
tained informed, written consent from each patient and/or the parent or
guardian. Patients were randomized to receive taliglucerase alfa 30 U/kg
or 60 U/kg per infusion every other week for 12 months.Efﬁcacy end points
The primary end point was the median percent change in hemoglo-
bin concentration from baseline and the interquartile range of median
percent change in hemoglobin levels from baseline. Secondary end
points included the percent changes from baseline in spleen volume,
liver volume, platelet counts, and either chitotriosidase or CCL18
activity.
Exploratory end points of organ volumes expressed as multiples of
normal (MN) were calculated using normal spleen volume = 2 mL/kg
multiplied by body weight in kg and normal liver volume = 25 mL/kg
multiplied by body weight in kg. Exploratory end points included:
change in height, weight, puberty, and bone age (based on radiograph
of the left hand and wrist); occurrence of bone events including bone
crises; and quality of life using Child Health Questionnaire™ (CHQ)
PF-28 (valid for patients aged 5 to 18 years).Safety end points
Safety end points included AEs and changes in clinical laboratory
ﬁndings, echocardiographic readings, and anti-taliglucerase alfa anti-
body titers. Occurrence of bone events, including bone crises, was part
of the analysis of AEs.Patients
Male and female patients aged 2 to b18 years were required to have
a diagnosis of GD with leukocyte acid beta-glucocerebrosidase activity
level ≤30% of the mean activity of the reference range for healthy
individuals. Patients were eligible if they had not received ERT in the
past or within the previous 12 months and had a negative anti-
glucocerebrosidase assay assessment, had not received substrate reduc-
tion therapy for GD in the past 12 months, and were judged in need of
treatment with ERT based on clinical condition and the opinion of the
local investigator. Patients were excluded based on any of the following
criteria: presence of complex neuronopathic features other than
longstanding oculomotor gaze palsy; unresolved anemia due to iron,
folic acid, or vitamin B12 deﬁciency; currently taking another investiga-
tional drug for any condition; previous hypersensitive reaction to
alglucerase or imiglucerase; history of allergy to carrots; inability of par-
ents or guardians to understand the nature, scope, and consequences of
study participation; and presence of any medical, behavioral, psycho-
logical/emotional condition thatwould, in the investigator's opinion, in-
terfere with full participation in the study.
Laboratory assessments
Spleen and liver volumes were measured using magnetic resonance
imaging as previously reported [15] and were assessed at BioClinica,
Lyon, France. Beta-glucocerebrosidase activity, chitotriosidase or CCL18
activity, and DNA sequencing were performed at a centralized laborato-
ry, the Academic Medical Center in Amsterdam, The Netherlands. The
reference range for beta-glucocerebrosidase activity level was b30% of
the normal reference at this laboratory. Hemoglobin concentration,
platelet counts, and dip-stick urinalysis were performed by local labora-
tories. Antibody assessments were performed by the Protalix clinical
laboratory.
Statistical analysis
Descriptive statisticswere obtained for continuous variables, sample
size, median, quartiles, mean, standard deviation, standard error (SE),
and range. Number and percentage of patients were calculated for
categorical variables. Study end points were not analyzed using
inferential statistics or stratiﬁed by study center. The sample size for
this study was not based on statistical consideration or power calcula-
tion, and was determined pragmatically due to the limited number of
pediatric patients with GD. A sample size of 10 (5 per study arm) was
considered adequate to evaluate the safety end points. A post hoc anal-
ysis was performed of hemoglobin concentration results in the subset of
patients who had anemia at baseline. Anemia was deﬁned as a
hemoglobin concentration b11.0 g/dL for patients 6 months to 4 years
of age, b11.5 g/dL for patients 5 to b12 years of age, b12.0 g/dL for
patients 12 to b15 years of age, b12.0 g/dL for female patients
≥15 years of age (b11.0 g/dL if pregnant) and b13.0 g/dL for male
patients ≥15 years of age [16].
Results
Patients
A total of 11 pediatric patients were screened and all were random-
ized to taliglucerase alfa: 6 in the 30-U/kg group and 5 in the 60-U/kg
group. All patients received study drug and completed the study; there
were no discontinuations. All were included in the efﬁcacy and safety
analyses. Eight of the patientsweremale, ninewere not of Jewish ethnic-
ity, and 10 were Caucasian–non-Hispanic/Latino children (Table 1).
Disease manifestations at baseline showed a wide variation between
and within treatment groups (Table 2). Mutational analysis and
Table 1
Patient demographics. Demographic characteristics at baseline.
Parameter Taliglucerase alfa
30 U/kg
(n = 6)
Taliglucerase alfa
60 U/kg
(n = 5)
Age, mean ± SD, y 9.5 ± 4.0 6.6 ± 3.1
(Range) (3–14) (2–10)
Male, n (%) 4 (66.7) 4 (80.0)
Female, n (%) 2 (33.3) 1 (20.0)
Ashkenazi Jewish, n (%) 0 2 (40.0)
Non-Jewish, n (%) 6 (100.0) 3 (60.0)
Caucasian, n (%) 6 (100.0) 4 (80.0)
Other, n (%) 0 1 (20.0)
Hispanic or Latino, n (%) 3 (50.0) 1 (20.0)
Non-Hispanic or Latino, n (%) 3 (50.0) 4 (80.0)
SD indicates standard deviation.
Fig. 1. Hemoglobin responses to taliglucerase alfa: absolute concentration and change
from baseline. (A) Mean concentration in g/dL; (B) mean percent change from baseline
to 12 months. Values are mean ± standard error.
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tient and Type 3c in another patient.
An average 34.7 U/kg of taliglucerase alfa (range, 30–45 U/kg) per
infusion was administered for the 30-U/kg treatment group, and
63.7 U/kg (range, 61–69 U/kg) per infusion was administered for the
60-U/kg treatment group. The dose was calculated according to patient
weight and was rounded up to a full vial.
Efﬁcacy
Hemoglobin concentration
The median percent changes from baseline in hemoglobin concen-
trations at month 12 (primary end point) were 12.2 and 14.2 for
taliglucerase alfa 30 and 60 U/kg, respectively; the interquartile ranges
ofmedian percent change in hemoglobin levels frombaselinewere 20.6
and 10.4, respectively. The mean (± SE) percent changes from baseline
in hemoglobin concentrations at month 12 were 13.8 (5.9) and 15.8
(3.7) for taliglucerase alfa 30 and 60 U/kg, respectively (Fig. 1). Mean
hemoglobin concentrations increased from baseline at all time points
in both the 30 U/kg and 60 U/kg groups (Table 2, Fig. 1). In theTable 2
Gaucher disease parameters. Disease characteristics at baseline and 12 months.
Taliglucerase alfa
30 U/kg (n = 6)
Disease parameter Baseline 12 mon
Hemoglobin, g/dL
Mean ± SE 11.3 ± 0.7 12.7 ± 0.5
Range 8–13 11–14
Hemoglobin, % change from baseline to 12 months
Median (IQR)a 12.2 (20.6)
Mean ± SE 13.8 ± 5.9
Range −2, 37
Spleen volume, MN
Mean ± SE 22.2 ± 5.0 14.0 ± 3.5
Range 9.0–41.2 6.6–30.2
Liver volume, MN
Mean ± SE 1.8 ± 0.2 1.5 ± 0.2
Range 1.1–2.7 1.0–2.3
Platelets, /mm3
Mean ± SE 162,667 ± 29,328 208,167 ±
Range 66,000–273,000 80,000–32
Chitotriosidaseb, nmol/mL*h
Mean ± SE 24,820 ± 7308 11,610 ± 4
Range 3598–49,733 1153–33,8
MN indicates multiples of normal, where normal spleen volume is 2 mL/kgmultiplied by body
indicates interquartile range; SE, standard error.
a Primary efﬁcacy end point.
b One patient in the 60-U/kg dose group, who was chitotriosidase deﬁcient, achieved a 57%taliglucerase alfa 30-U/kg and 60-U/kg groups, absolute changes in
mean hemoglobin concentrations were +1.4 and +1.6 g/dL, respec-
tively, by study end. Individual patient data are reported in Table 3.Taliglucerase alfa
60 U/kg (n = 5)
ths Baseline 12 months
10.6 ± 0.6 12.2 ± 0.5
9–12 11–14
14.2 (10.4)
15.8 ± 3.7
5, 26
29.4 ± 10.8 12.9 ± 3.2
10.0–69.3 6.2–24.6
2.2 ± 0.2 1.7 ± 0.1
1.8–3.0 1.4–2.0
37,047 99,600 ± 19,185 172,200 ± 39,932
4,000 76,000–176,000 88,000–308,000
865 34,961 ± 11,040 14,433 ± 7267
02 15,420–63,179 1056–34,695
weight (kg) and the normal liver volume is 25 mL/kg multiplied by bodyweight (kg); IQR
reduction in CCL18 activity.
Table 3
Individual efﬁcacy results. Patient data for organ volume, hematologic parameters, and biomarker activity at baseline and following 12 months of taliglucerase alfa treatment.
Patient
ID
Gender Age at IC
signature
(years)
Spleen volume
at baseline
(mL) (MN)
Spleen volume
at month
12 (mL) (MN)
Hb concentration
at baseline
(g/dL)
Hb change
(g/dL)
Liver volume
at baseline
(mL) (MN)
Liver volume
at month
12 (mL) (MN)
Platelet count
at baseline
(/mm3)
Platelet count
change
(/mm3)
Chitotriosidase
activity (nmol/ml.h)
at baseline
% change CCL18 activity
(ng/mL)
at baseline
% change
60 U/kg/infusion
10–5001 M 10.7 1615.53 798.28 11.3 1.6 1223.05 1026.39 76,000 43,000 41,732 −65.98% 2230 −50.81%
35.1 14.5 2.1 1.5
10–5007 M 2.4 354.89 248.76 9.2 2.0 611.79 583.90 80,000 51,000 19,513 −60.10% 1239 −56.58%
14.2 8.3 2.0 1.6
11–5004 F 5.7 325.35 216.99 12.3 1.4 739.35 615.36 79,000 136,000 15,420 −93.15% 611 −80.36%
10.0 6.2 1.8 1.4
11–5005 M 8.4 1996.01 786.28 9.1 2.4 1089.67 800.66 87,000 1000 63,179 −45.08% 1618 −17.74%
69.3 24.6 3.0 2.0
91–5010a M 8.7 823.67 569.60 11.1 0.6 1294.85 1219.12 176,000 132,000 NAa NAa 999 −57.36%
18.4 11.0 2.3 1.9
30 U/kg/infusion
10–5002b M 3.2 240.02 222.14b 12.2 −0.3 474.97 525.21b 145,000 −12,000 6892 −68.21% 363 −53.72%
9.0 7.1 1.4 1.3
10–5003 M 14.2 1086.37 1074.69 11.6 0.2 1104.56 991.72 66,000 14,000 3598 −67.95% 283 −53.36%
13.6 13.8 1.1 1.0
11–5006 M 8.4 839.56 452.69 11.3 1.9 1443.76 1293.55 273,000 10,000 39,256 −74.54% 907 −69.57%
14.0 6.6 1.9 1.5
91–5008 M 11.5 1549.83 737.99 13.2 1.0 1248.84 1122.17 204,000 120,000 25,575 −67.24% 1533 −66.01%
28.3 12.0 1.8 1.5
91–5009 F 13.6 2061.94 1188.11 11.2 2.5 1749.63 1642.37 172,000 42,000 23,865 −40.75% 1414 −45.40%
27.0 14.1 1.8 1.6
91–5011 F 8.3 1532.07 1194.00 8.2 3.0 1265.18 1119.56 116,000 99,000 49,733 −32.03% 2336 −15.33%
41.2 30.2 2.7 2.3
F, female; Hb, hemoglobin; IC, informed consent; M, male; MN, multiples of normal; NA, not available.
a Patient 91-5010 did not show chitotriosidase activity.
b Patient 10-5002 had an increase in weight of 17% (+2.3 kg) from baseline, which is reﬂected in the increase in absolute liver volume; this is accounted for in the evaluation by multiples of normal.
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Fig. 2. Response of spleen volume, liver volume, platelet counts, and chitotriosidase activity to taliglucerase alfa. (A)Mean spleen volume inMNwhere normal spleen volume= 2 mL/kg
multiplied by bodyweight in kg; and (B) mean percent change in spleen volume from baseline to 12 months; (C)mean liver volume inMNwhere normal liver volume= 25 mL/kgmul-
tiplied by body weight in kg; (D) mean percent change in liver volume from baseline to 12 months; (E) mean percent change in platelet counts from baseline to 12 months; (F) mean
percent change in chitotriosidase activity from baseline to 12 months. Mean percent changes in spleen and liver volumes are calculated from absolute organ volumes inmL. MN indicates
multiples of normal. *One patient in the 60-U/kg dose group, whowas chitotriosidase deﬁcient and did not havemeasurable levels of chitotriosidase activity, was excluded from this anal-
ysis. Values are mean ± standard error.
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baseline showed a mean increase of 1.9 and 1.7 g/dL in absolute hemo-
globin concentrations by study end for the taliglucerase alfa 30-U/kg
and 60-U/kg groups, respectively (Table 4). Six (75%) of the 8 patientsTable 4
Hemoglobin concentration. Mean changes in hemoglobin concentration for patients who
had anemia at baseline.
Taliglucerase alfa
30 U/kg
(n = 6)
Taliglucerase alfa
60 U/kg
(n = 5)
Number of patients with anemiaa 4 4
Mean hemoglobin concentration
at baseline ± SE, g/dL
10.6 ± 0.8 10.2 ± 0.6
Mean hemoglobin concentration
at study end ± SE, g/dL
12.5 ± 0.6 11.8 ± 0.4
Mean change from baseline at
study end ± SE, g/dL
+1.9 ± 0.6 +1.7 ± 0.4
SE indicates standard error.
a Anemia was deﬁned as a hemoglobin concentration b11.0 g/dL for patients 6 months
to 4 years of age, b11.5 g/dL for patients 5 to b12 years of age, b12.0 g/dL for patients
12 to b15 years of age, b12.0 g/dL for females ≥15 years of age (b11.0 g/dL if pregnant)
and b13.0 g/dL for males ≥15 years of age.no longer had anemia at study end; the 2 patients (25%) who had ane-
mia at study endwere in the 30-U/kg group and had achieved hemoglo-
bin concentrations that approached normal by study end (11.2 and
11.8 g/dL, respectively).
Spleen volume, liver volume, platelet counts, and chitotriosidase activity
From baseline to 12 months, improvements were observed in organ
volumes and platelet counts (Table 2, Fig. 2). Mean spleen volumes
were reduced from 22.2 MN at baseline to 14.0 MN at 12 months and
29.4 MN at baseline to 12.9 MN at 12 months for taliglucerase alfa
30 U/kg and 60 U/kg, respectively (Fig. 2A). At 12 months, mean abso-
lute spleen volume (calculated by volume in mL) decreased by 28.6%
and 41.1% from baseline for patients receiving taliglucerase alfa
30 U/kg and 60 U/kg, respectively (Fig. 2B). Mean liver volumes were
reduced from 1.8 MN at baseline to 1.5 MN at 12 months and 2.2 MN
at baseline to 1.7 MN at 12 months, for the taliglucerase alfa 30-U/kg
and 60-U/kg groups, respectively (Fig. 2C). Mean absolute liver volume
(calculated by volume in mL) was reduced from baseline to 12 months
by 6.3% and 14.0%, for the taliglucerase alfa 30-U/kg and 60-U/kg
groups, respectively (Fig. 2D). After 12 months of treatment, mean per-
cent change in platelet counts improved by 30.9% (from 162,667 to
208,167/mm3) for the 30-U/kg dose group and by 73.7% (from 99,600
Table 5
Adverse events. Number of adverse events by severity, taliglucerase alfa dose group, and
relationship to treatment.
No. of AEs
(no. of patients [n = 11])
Percentage
of total AEs
Total adverse events 53 (10) 100
Mild or moderate 51 (9) 96.2
30 U/kg 21 (4)
60 U/kg 30 (5)
Severe or very severe 2 (2) 3.8
30 U/kga 1 (1)
60 U/kgb 1 (1)
Non-treatment related 45 (10) 84.9
Treatment related 8 (2) 15.1
AEs indicate adverse events.
a Pulmonary hypertension in a Type 3c Gaucher disease patient; not treatment related.
b Gastroenteritis; treatment related.
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chitotriosidase activitywas reduced by58.5% and 66.1% after 12 months
of treatment with taliglucerase alfa 30 U/kg and 60 U/kg, respectively
(Fig. 2F). Individual patient data for these parameters are reported in
Table 3.
Growth and development
Increases in height and weight were seen at the end of the study in
both dose groups, with increases in mean (±SD) height of 4.2%
(±2.2) and 7.6% (±2.1) and mean increases in weight of 9.6% (±7.0)
and 14.7% (±5.7) in the30-U/kg and 60-U/kg treatment groups, respec-
tively. Post hoc analysis of height velocity showed that the taliglucerase
alfa 30-U/kg group had a mean growth of 5.1 cm/year and the 60-U/kg
treatment group had a mean growth of 8.0 cm/year after 12 months'
treatment of taliglucerase alfa.
There was no change in puberty (Tanner stage) in 4/5 patients from
baseline to study end in the 60-U/kg dose group (data not available for 1
patient; all patients≤10 years of age and at stage I at baseline). Of the 6
patients treated with taliglucerase alfa 30 U/kg, 2 patients (14 and
11 years of age) had a change in Tanner stage from I to II, 1 patient
remained at Tanner stage III, and the other 3 patients remained at Tan-
ner stage I.
The mean (SE) bone age determined by X-ray of the left hand and
wrist increased by 1.9 (0.7) years and 1.4 (0.1) years in the taliglucerase
alfa 30-U/kg and 60-U/kg groups, respectively. In the taliglucerase alfa
30-U/kg group, 2 patients whose bone age was not evaluated at day 1
or at the end of study were not included in the analysis. At baseline,
bone age for all treated patients was considered to be delayed, relative
to chronological age, except for one 13-year-old patient, whose bone
age was equivalent to chronological age at baseline. After 12 months
of treatmentwith taliglucerase alfa in the 9 pediatric patients evaluated,
2 in each treatment group showed approximately 1 year of bone age ad-
vancement, 3 patients in the taliglucerase alfa 60-U/kg treatment group
and 1 in the 30-U/kg treatment group showed 1.5 to 1.75 years of bone
age advancement, and one 11-year-old patient in the taliglucerase alfa
30-U/kg treatment group showed 4 years of bone age advancement.
Z-scores from bone mineral density analysis by dual energy X-ray
absorptiometry showed mean (± SE) decreases at the lumbar spine of
−0.20 (±0.20; n = 6) and femoral neck of−0.30 (±0.28; n = 5) in
the taliglucerase alfa 30-U/kg dose group and mean (± SE) increases
at the lumbar spine of 0.27 (±0.05; n = 4) and femoral neck 0.20
(±0.421; n = 4) in the taliglucerase alfa 60-U/kg dose group.
Responses to the CHQ for Quality of Life assessment, showed that
after 12 months of treatment with taliglucerase alfa, more parents/
guardians rated their children's global health as very good or excellent
(3/11 at baseline vs. 7/11 at month 12). At baseline, 3/11 parents/
guardians believed their children to be in much better or somewhat
better health than 1 year ago as compared with 9/11 after
12 months' treatment with taliglucerase alfa. In addition, the par-
ents/guardians had less emotional worry or concern about their
child's physical health (6/11 had “quite a bit” or “a lot” of worry or
concern at baseline vs. 1/11 at month 12) and had less limitation
to their time because of their child's physical health (4/11 were lim-
ited “a lot” at baseline vs. 0/11 at month 12).
Safety
Of the 11 taliglucerase alfa–treated patients, 10 (5 in each of the dose
groups) experienced 53 AEs (22 and 31 in the taliglucerase alfa 30- and
60-U/kg groups, respectively). One patient in the taliglucerase alfa
60-U/kg group experienced a serious AE during the ﬁrst infusion visit
(gastroenteritis, requiring hospitalization for rehydration) that resolved
after 1 day; the patient continues on treatment with intermittent anti-
histamine use. This serious AE was re-evaluated as treatment-related
after recurrence during the second infusion. No patient was diagnosed
with a GD-related bone crisis during the study. One patient in thetaliglucerase alfa 30-U/kg group experienced bone pain in an extremity
(bone pain in the bottomof the feet) but thiswas not considered related
to GD or treatment.
Most AEs were mild-to-moderate in nature, transient, and not relat-
ed to treatment (Table 5). Two patients in the 60-U/kg treatment group
experienced 8 events that were considered to be treatment-related by
the investigator; the ﬁrst patient reported 3 occurrences of itchy throat
and 1 occurrence of chest discomfort, and the second patient reported 1
occurrence of gastroenteritis and 3 occurrences of vomiting. Both pa-
tients were pre-medicated with H1 blockers and are continuing in the
extension study. No patient withdrew from this trial due to an AE.
No clinically signiﬁcant laboratory test abnormalities (hematology,
serum and urinary chemistry) were noted. There were no clinically sig-
niﬁcantmean changes from baseline observed at the end of the study in
any of the laboratory safety parameters. The majority of the vital sign
measurements were within normal limits, none of the changes or the
measurements outside of the normal limits were clinically signiﬁcant.
Abnormal echocardiography results at month 12 were reported for 2
patients: One patient receiving the 60-U/kg dose had mild tricuspid re-
gurgitation and 1 patient in the 30-U/kg group diagnosed with Type 3c
GD (subtype known to have a cardiac involvement) [1,17,18] had a
baseline echocardiography that revealed abnormal atrioventricular
and mitral valves with an insufﬁciency gradient of 30 mm Hg. At
study end, the echocardiography results showed pulmonary hyperten-
sion with an abnormal tricuspid insufﬁciency gradient of 74 mm Hg,
which was considered a clinically signiﬁcant deterioration but was
deemed not related to study treatment.
Immunogenicity
Two patientswere found to be IgG positive for anti-taliglucerase-alfa
antibodies in at least 1 post-treatment visit; however, this ﬁnding did
not affect the continued improvement of GD parameters throughout
the course of the study. An additional patient was found to be IgG pos-
itive at the pretreatment sample and became negative as the trial
progressed; this patient also improved clinically as noted above for
the other 2 patients. All positive titers were low (b550). Assay results
for neutralizing antibodies (in vitro enzymatic inhibition assay and
cell-based neutralizing assay)were negative for all 3 patients. No appar-
ent associationwas noted between anti-taliglucerase antibody and safe-
ty or efﬁcacy.
Discussion
This study is distinguished among studies of ERT for GD in that it is
focused exclusively on treatment-naïve pediatric patients. This pediatric
study followed the design of the pivotal study in adults regarding dos-
age, wherein patients were randomized to receive taliglucerase alfa ei-
ther 30 or 60 U/kg, every other week. However, in this study, the
duration was 12 months instead of 9 months and the primary end
15A. Zimran et al. / Blood Cells, Molecules and Diseases 54 (2015) 9–16point was improvement in hemoglobin rather than reduction in spleen
volume. At the end of this study, clinically signiﬁcant improvements
were observed in hemoglobin concentration, platelet counts, spleen
volume, and liver volume, as well as in GD biomarkers. Notably, re-
sponses were seen as early as 3 months from the start of therapy and
continued through 12 months.
The improvements in visceral and hematologicmanifestations of GD
observed during the 12 months of treatment with taliglucerase alfa in
this pediatric populationwere generally consistentwith ﬁndings for pe-
diatric patients receiving imiglucerase and velaglucerase alfa [19–21]. In
addition, the safety ﬁndings and the magnitude of efﬁcacy responses in
the current trial were consistent with those from the phase 3 pivotal
taliglucerase alfa trial in adults [14,21]. The safety proﬁle does not differ
between the 30- and 60-U/kg dose groups. All patients ﬁnished the
52-week study, and 10 of the 11 patients continued on to the extension
trial (PB-06-006). Premedication with H1 blockers (in the single pa-
tient) prevented drug-related adverse effects and did not affect the pos-
itive response to treatment.
Anemia has been shown to occur in 40% of pediatric patients with
non-neuronopathic GD [6] and may be more severe than in patients
with GD with later onset [1]. However, in the present study, 8/11
patients (73%) had anemia at baseline and, thus, more patients had ane-
mia than typically encountered in pediatric patients with GD. Of the 8
patients who had anemia at baseline, 6 showed resolution of anemia
by month 12, including all of the patients receiving the 60-U/kg dose;
the other 2 patients showed signiﬁcant clinical improvement that
approached normal. The clinical relevance of improving anemia in pa-
tients with GD may extend beyond direct hematologic considerations,
as anemia has been shown to be a risk factor for avascular osteonecrosis
in patients with GD [22].
Pediatric patients with Type 1 GD may develop growth retardation
and pubertal delay [8,23], which are unique features not relevant to
adult populations. In addition, bone involvement begins early in life
and low bone mineral density may begin as early as 5 years of age and
is putatively most prevalent in adolescence [24]. Because bone disease
and its related disability are signiﬁcant sources of long-term morbidity
[24] and adversely impacts quality of life [25] in patients with GD, ad-
dressing this disease manifestation early in life is of key importance to
achieve optimal peak bone mass and minimize bone-related disease
manifestations. To examine features of growth and development, ex-
ploratory analyses in the present trial included assessment of changes
in: height, weight, puberty, bone age, and bone mineral density, occur-
rence of bone crises, and quality of life.While the trendwas toward pos-
itive ﬁndings, the study duration was too short to adequately assess
these parameters.
The interpretation of ﬁndings from this study is limited by the small
number of patients, which precluded analysis of variance of changes
from baseline and comparisons between doses. The positive results
found in the present study support the collective experience of more
than 20 years that children respond similarly to adults to ERT for GD
and that the dose is determined primarily by bodyweight. As noted, an-
other limitation is that the 12-month study period was too short to ad-
equately capture improvements in pediatric-speciﬁc parameters such
as puberty (as evaluated by Tanner stage) and bone mineral density
analysis. However, these parameters will continue to be followed in
extension study PB-06-006 (NCT01411228) that will capture an addi-
tional 2 years of data for a total of 3 years of taliglucerase alfa treatment.
Conclusions
In summary, this report demonstrates that taliglucerase alfa im-
proves the hematologic and visceral manifestations of Gaucher disease
in children. It broadens the ﬁndings to date of the safety and efﬁcacy
of taliglucerase alfa in patients with GD, pediatric and adult patients
alike, and as such expands the potential treatment options for manage-
ment of this genetic metabolic disorder.Authorship contribution
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